The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 27, 2019

Filed:

Sep. 26, 2018
Applicant:

Pulse Biosciences, Inc., Hayward, CA (US);

Inventors:

Richard Lee Nuccitelli, Millbrae, CA (US);

Pamela S. Nuccitelli, Millbrae, CA (US);

Joanne Lum, San Francisco, CA (US);

Kaying Lui, Millbrae, CA (US);

Brian G. Athos, San Francisco, CA (US);

Mark P. Kreis, San Francisco, CA (US);

Zachary R. Mallon, San Francisco, CA (US);

Jon Berridge, Oakland, CA (US);

Assignee:

PULSE BIOSCIENCES, INC., Hayward, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61N 1/36 (2006.01); A61K 35/13 (2015.01); A61B 18/14 (2006.01); C12N 13/00 (2006.01); A61N 1/05 (2006.01); A61N 1/32 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 5/09 (2010.01); G01N 33/574 (2006.01); A61N 1/00 (2006.01); C12N 15/87 (2006.01); A61B 18/00 (2006.01); A61N 1/40 (2006.01); C12M 1/42 (2006.01); A61N 1/04 (2006.01); A61N 1/372 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/13 (2013.01); A61B 18/1477 (2013.01); A61K 31/704 (2013.01); A61K 39/395 (2013.01); A61K 39/39558 (2013.01); A61N 1/00 (2013.01); A61N 1/05 (2013.01); A61N 1/32 (2013.01); A61N 1/36 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C12N 5/0693 (2013.01); C12N 13/00 (2013.01); G01N 33/574 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/00613 (2013.01); A61K 2039/505 (2013.01); A61N 1/0412 (2013.01); A61N 1/0424 (2013.01); A61N 1/327 (2013.01); A61N 1/37229 (2013.01); A61N 1/40 (2013.01); C07K 2317/76 (2013.01); C12M 35/02 (2013.01); C12N 15/87 (2013.01); C12N 2501/599 (2013.01); C12N 2501/999 (2013.01);
Abstract

Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.


Find Patent Forward Citations

Loading…